Smith L. Mary's Insider Trades & SAST Disclosures
Smith L. Mary's most recent trade in SpringWorks Therapeutics Inc was a trade of 60,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 4, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Smith L. Mary.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 21,156 | 239,095 (0%) | 0% | 0 | Common Stock | |
| SpringWorks Therapeutics Inc | Smith L. Mary | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.53 per share. | 04 Jan 2024 | 3,535 | 233,363 (0%) | 0% | 41.5 | 146,809 | Common Stock |
| SpringWorks Therapeutics Inc | Smith L. Mary | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.96 per share. | 04 Jan 2024 | 2,197 | 236,898 (0%) | 0% | 38.0 | 83,398 | Common Stock |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 5,720 | 217,939 (0%) | 0% | - | Common Stock | |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.41 per share. | 07 Jan 2023 | 1,068 | 212,219 (0%) | 0% | 26.4 | 28,206 | Common Stock |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 22,663 | 215,739 (0%) | 0% | - | Common Stock | |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.52 per share. | 05 Jan 2023 | 2,452 | 213,287 (0%) | 0% | 27.5 | 67,479 | Common Stock |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.47 per share. | 18 Jul 2022 | 1,551 | 193,076 (0%) | 0% | 28.5 | 44,157 | Common Stock |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 6,092 | 194,627 (0%) | 0% | 0 | Common Stock | |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.06 per share. | 07 Jan 2022 | 1,181 | 188,535 (0%) | 0% | 56.1 | 66,207 | Common Stock |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 69,207 | 69,207 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 22,205 | 189,716 (0%) | 0% | - | Common Stock | |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 13 Oct 2021 | 10,000 | 177,511 (0%) | 0% | 2.3 | 23,000 | Common Stock |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 10,000 | 84,296 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 55.97 per share. | 13 Oct 2021 | 10,000 | 167,511 (0%) | 0% | 56.0 | 559,675 | Common Stock |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 13 Jul 2021 | 10,000 | 177,511 (0%) | 0% | 2.3 | 23,000 | Common Stock |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 10,000 | 94,296 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 80.88 per share. | 13 Jul 2021 | 10,000 | 167,511 (0%) | 0% | 80.9 | 808,777 | Common Stock |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 13 Apr 2021 | 10,000 | 177,511 (0%) | 0% | 2.3 | 23,000 | Common Stock |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 10,000 | 104,296 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 68.07 per share. | 13 Apr 2021 | 10,000 | 167,511 (0%) | 0% | 68.1 | 680,723 | Common Stock |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 78.70 per share. | 20 Jan 2021 | 10,000 | 167,511 (0%) | 0% | 78.7 | 787,016 | Common Stock |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 20 Jan 2021 | 8,872 | 177,511 (0%) | 0% | 2.3 | 20,406 | Common Stock |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2021 | 8,872 | 114,296 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2021 | 1,128 | 1,451 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.65 per share. | 20 Jan 2021 | 1,128 | 168,639 (0%) | 0% | 1.6 | 1,861 | Common Stock |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 88,000 | 88,000 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | L. Mary Smith | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 11,000 | 167,511 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges